EU green light for antidepressant Brintellix
The European Commission has granted Lundbeck its marketing authorization to sell vortioxetine (Brintellix) for the treatment of adults with depression.
The latest regulatory approval follows that given by the FDA in the US in September 2013.
"The approval of Brintellix marks yet another step for Lundbeck in a very successful year.
"With its novel multimodal mechanism of action, we are confident that Brintellix advances both the science and the treatment of a complex and heterogeneous disease consisting of emotional, physical and cognitive symptoms."
Anders Gersel Pedersen, executive vice-president and head of R&D, Lundbeck.
The company announced on Friday, December 27th, that it had received the European Medicines Agency's decision.
Vortioxetine has effects on a number of serotonin (5-hydroxytryptamine or 5-HT) receptors, Lundbeck said: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3 and 5-HT7; and also inhibits the 5-HT transporter.
Related news:
Lundbeck gets EU marketing approval for Brintellix (Reuters).
Reference links:
Lundbeck receives European marketing authorization for Brintellix for the treatment of adults with major depressive episodes (Lundbeck press release).
